AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21987227 — intervention group
Group type: COMPARATOR
Intervention: 3‐month waitlist
Number of subjects: 24
Study 20151520 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator and femoral cutaneous nerve blocks
Number of subjects: 75
Study 20151520 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous analgesia
Number of subjects: 75
Study 17164979 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol cocoa (329 mg flavanols, 61 mg epicatechin per 100 ml)
Number of subjects: 10
Study 17164979 — intervention group
Group type: COMPARATOR
Intervention: Low flavanol cocoa (27 mg flavanols, 6.6 mg epicatechin per 100 ml)
Number of subjects: 10
Study 15078803 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 1314
Study 12006189 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulse flashlamp pumped pulsed dye laser (LPDL)
Number of subjects: 15
Study 12006189 — intervention group
Group type: COMPARATOR
Intervention: Cryogen coolant only
Number of subjects: 15
Study 12006189 — intervention group
Group type: EXPERIMENTAL
Intervention: LPDL
Number of subjects: 15
Study 9835727 — intervention group
Group type: EXPERIMENTAL
Intervention: SP Group (single shot spinal anesthesia)
Number of subjects: 64
Study 9835727 — intervention group
Group type: COMPARATOR
Intervention: PD Group (continuous epidural anesthesia)
Number of subjects: 64
Study 9835727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 8008484 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulable phosphor technology
Number of subjects: 100
Study 8008484 — intervention group
Group type: COMPARATOR
Intervention: Conventional screen-film technology
Number of subjects: 100
Study 3627579 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol plus hospitalization
Number of subjects: 200
Study 3627579 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization alone
Number of subjects: 200
Study 31919539 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messages using mobile phone SMS messages 2-3 times per week
Number of subjects: 2062
Study 31919539 — intervention group
Group type: COMPARATOR
Intervention: Standard advice on a healthy lifestyle
Number of subjects: 2062
Study 29674362 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the ACI model of care for acute low back pain, including educational materials and seminars, and an audit and feedback approach.
Number of subjects: 200
Study 29674362 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control period).
Number of subjects: 200
Study 26378118 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/ω-3 PUFA-enriched IVFE
Number of subjects: 60
Study 26378118 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil-based IVFE
Number of subjects: 60
Study 23574694 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for Health-Promoting Schools (SHPS)
Number of subjects: 728
Study 23574694 — intervention group
Group type: EXPERIMENTAL
Intervention: School nutrition services (3-item, α = 0.87)
Number of subjects: 728
Study 23574694 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy school policies (6-item, α = 0.87)
Number of subjects: 728
Study 23574694 — intervention group
Group type: EXPERIMENTAL
Intervention: School's physical environment (10-item, α = 0.91)
Number of subjects: 728
Study 23574694 — intervention group
Group type: EXPERIMENTAL
Intervention: School's social environment (4-item, α = 0.88)
Number of subjects: 728
Study 23574694 — intervention group
Group type: EXPERIMENTAL
Intervention: Community links (6-item, α = 0.91)
Number of subjects: 728
Study 23574694 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual health skills and action competencies (3-item, α = 0.89)
Number of subjects: 728
Study 23574694 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services (5-item, α = 0.86)
Number of subjects: 728
Study 22317387 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved land preparation tools (clod breaker, improved plough/'danella')
Number of subjects: 1800
Study 22317387 — intervention group
Group type: COMPARATOR
Intervention: Traditional tools
Number of subjects: 1800
Study 22317387 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved land preparation tools
Number of subjects: 1800
Study 20456814 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein meal
Number of subjects: 22
Study 17805486 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Vinorelbine (GV)
Number of subjects: 39
Study 17805486 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Docetaxel (GD)
Number of subjects: 39
Study 19172341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribonuclease-enriched lactoferrin (R-ELF) supplement
Number of subjects: 38
Study 16360958 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release metoprolol succinate
Number of subjects: 100
Study 16360958 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 100
Study 11848031 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy using allogenic leukocytes from the partner
Number of subjects: 0
Study 11848031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 11848031 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9394162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glucose, amino acids, and emulsion enriched in essential fatty acids (EFAs)
Number of subjects: 30
Study 9394162 — intervention group
Group type: COMPARATOR
Intervention: Non-EFAs treated cases (control group)
Number of subjects: 30
Study 7967861 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice guideline for early transfer of low-risk patients with CHF 24 hours after hospital admission, supported by personalized reminders.
Number of subjects: 90
Study 7967861 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice guideline implementation
Number of subjects: 90
Study 3631497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia with enflurane
Number of subjects: 50
Study 3631497 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia with enflurane and fentanyl
Number of subjects: 50
Study 30843712 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative evaluative conditioning (EC)
Number of subjects: 0
Study 30843712 — intervention group
Group type: COMPARATOR
Intervention: Neutral evaluative conditioning (EC)
Number of subjects: 0
Study 30843712 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative evaluative conditioning (EC) with focus on feelings
Number of subjects: 0
Study 30843712 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative evaluative conditioning (EC) with focus on knowledge
Number of subjects: 0
Study 27545848 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 0
Study 25692479 — intervention group
Group type: EXPERIMENTAL
Intervention: TiZr implants
Number of subjects: 10
Study 25692479 — intervention group
Group type: COMPARATOR
Intervention: cpTi implants
Number of subjects: 10
Study 25692479 — intervention group
Group type: EXPERIMENTAL
Intervention: TiZr and cpTi implants
Number of subjects: 10
Study 24971004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM) 2 mg nightly for 24 weeks
Number of subjects: 80
Study 24971004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM) 2 mg nightly for 24 weeks in comorbid insomnia subgroup
Number of subjects: 80
Study 24971004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23060506 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC+RABORAL V‐RG
Number of subjects: 40
Study 23060506 — intervention group
Group type: EXPERIMENTAL
Intervention: RABORAL V‐RG
Number of subjects: 40
Study 23060506 — intervention group
Group type: EXPERIMENTAL
Intervention: chitosan+RABORAL V‐RG
Number of subjects: 40
Study 23060506 — intervention group
Group type: COMPARATOR
Intervention: no vaccine
Number of subjects: 40
Study 18668682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 10 weeks
Number of subjects: 25
Study 18668682 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg twice daily for 10 weeks
Number of subjects: 25
Study 18668682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17352021 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal EGD (TN‐EGD)
Number of subjects: 160
Study 17352021 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral EGD (TO‐EGD)
Number of subjects: 160
Study 17352021 — intervention group
Group type: COMPARATOR
Intervention: Conventional EGD (C‐EGD)
Number of subjects: 160
Study 15129926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/d of supplemental calcium
Number of subjects: 23
Study 15129926 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 23
Study 11794170 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional localized dose of 16 Gy radiation (given in eight fractions by external electron beam)
Number of subjects: 5318
Study 11794170 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (50 Gy radiation to the whole breast)
Number of subjects: 5318
Study 11794170 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional localized dose of 16 Gy radiation (for patients 40 years old or younger)
Number of subjects: 5318
Study 11794170 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (for patients 40 years old or younger)
Number of subjects: 5318
Study 11794170 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (for patients aged 41 to 50 years)
Number of subjects: 5318
Study 9478309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 42
Study 9478309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8200217 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 380A (TCu 380A) IUD
Number of subjects: 0
Study 8200217 — intervention group
Group type: COMPARATOR
Intervention: Copper T 200 (TCu 200) IUD
Number of subjects: 0
Study 2822334 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 5
Study 2822334 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 5
Study 2822334 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study 29614276 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose misoprostol
Number of subjects: 250
Study 29614276 — intervention group
Group type: COMPARATOR
Intervention: multiple-dose misoprostol
Number of subjects: 250
Study 27450392 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (2 g QDS or reduced according to renal function) for 6 months
Number of subjects: 50
Study 27450392 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment for 6 months
Number of subjects: 50
Study 24333108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 23764238 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg TSU-68 twice daily
Number of subjects: 103
Study 23764238 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 103
Study 19897460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-workload myocardial ischaemia (p-EST) followed by maximal exercise stress test (EST-2)
Number of subjects: 20
Study 19897460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-workload myocardial ischaemia (p-EST)
Number of subjects: 20
Study 18548577 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA stimulation (high-frequency rTMS over the supplementary motor area)
Number of subjects: 99
Study 18548577 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo control)
Number of subjects: 99
Study 16970100 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Kangjia Recipe (KR) combined with propylthiouracil (PTU)
Number of subjects: 90
Study 16970100 — intervention group
Group type: COMPARATOR
Intervention: Propylthiouracil (PTU) alone
Number of subjects: 90
Study 11854874 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate extubation (within 1 hour of surgery)
Number of subjects: 35
Study 11854874 — intervention group
Group type: COMPARATOR
Intervention: Short-term mechanical ventilation (3 hours)
Number of subjects: 35
Study 11854874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (immediate extubation and mechanical ventilation)
Number of subjects: 35
Study 10396718 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-ml 0.125% bupivacaine administered twice daily for 4 days
Number of subjects: 50
Study 10396718 — intervention group
Group type: COMPARATOR
Intervention: Saline administered twice daily for 4 days
Number of subjects: 50
Study 10396718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received treatment
Number of subjects: 50
Study 10396718 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-ml 0.125% bupivacaine administered
Number of subjects: 50
Study 7551329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic laparoscopic coagulating shears
Number of subjects: 31
Study 7551329 — intervention group
Group type: COMPARATOR
Intervention: Clipping method
Number of subjects: 31
Study 2328177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.4‐0.5 mg kg‐1
Number of subjects: 30
Study 2328177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.07‐0.08 mg kg‐1
Number of subjects: 30
Study 2328177 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.2‐0.3 mg kg‐1
Number of subjects: 30
Study 6968184 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aortic cross‐clamping
Number of subjects: 480
Study 6968184 — intervention group
Group type: COMPARATOR
Intervention: Intermittent aortic cross‐clamping
Number of subjects: 480
Study 30371552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure unilateral rhythmic movement therapy consisting of 12 sessions over 1 month, involving straight or circular rhythmic movements with robotic assistance.
Number of subjects: 13
Study 27344569 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction wound drainage (Group A)
Number of subjects: 56
Study 27344569 — intervention group
Group type: COMPARATOR
Intervention: No tube drainage (Group B)
Number of subjects: 56
Study 25900353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of forced expiratory volume at 1 second (FEV1)
Number of subjects: 3811
Study 25900353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of forced vital capacity (FVC)
Number of subjects: 3811
Study 25900353 — intervention group
Group type: COMPARATOR
Intervention: Percentage emphysema
Number of subjects: 3811
Study 23481119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (leuprolide)
Number of subjects: 20
Study 21294869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 3908
Study 21294869 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3908
Study 19661195 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo acupuncture with warm empathic interaction (Augmented)
Number of subjects: 289
Study 19661195 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo acupuncture with neutral interaction (Limited)
Number of subjects: 289
Study 19661195 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (Waitlist)
Number of subjects: 289
Study 17259203 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 17259203 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 17259203 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record
Number of subjects: 0
Study 15357767 — intervention group
Group type: EXPERIMENTAL
Intervention: rAHF-PFM
Number of subjects: 111
Study 15357767 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic regimen adherence
Number of subjects: 111
Study 11491421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir 900 mg twice daily
Number of subjects: 62
Study 11491421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir 1050 mg twice daily
Number of subjects: 62
Study 11491421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir 1200 mg twice daily
Number of subjects: 62
Study 11491421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir/Abacavir 900 mg twice daily (combination therapy)
Number of subjects: 62
Study 9536859 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (40 mg)
Number of subjects: 12
Study 9536859 — intervention group
Group type: EXPERIMENTAL
Intervention: lycopene (38 mg)
Number of subjects: 12
Study 9536859 — intervention group
Group type: EXPERIMENTAL
Intervention: lutein (31.2 mg)
Number of subjects: 12
Study 9536859 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene
Number of subjects: 12
Study 9536859 — intervention group
Group type: EXPERIMENTAL
Intervention: lycopene
Number of subjects: 12
Study 9536859 — intervention group
Group type: EXPERIMENTAL
Intervention: lutein
Number of subjects: 12
Study 7625111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral RRV-TV rotavirus vaccine with IPV
Number of subjects: 100
Study 7625111 — intervention group
Group type: COMPARATOR
Intervention: Oral RRV-TV rotavirus vaccine with OPV
Number of subjects: 100
Study 2773899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS) 30 ml (525 mg) q.i.d. for 21 days
Number of subjects: 20
Study 2773899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2773899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 20
Study 152612 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 6‐aminonicotinamide (6‐AN) gel
Number of subjects: 99
Study 152612 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 6‐aminonicotinamide (6‐AN)
Number of subjects: 99
Study 152612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 6‐AN and oral niacinamide therapy
Number of subjects: 99
Study 152612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 6‐AN
Number of subjects: 99
Study 29587297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin (0.2 g) treatment twice daily for 2 weeks along with intravenous antibiotic therapy
Number of subjects: 143
Study 29587297 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy alone
Number of subjects: 143
Study 29587297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin treatment
Number of subjects: 143
Study 29587297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study 27669971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tristel Trio Wipes
Number of subjects: 0
Study 27669971 — intervention group
Group type: EXPERIMENTAL
Intervention: PeraSafe
Number of subjects: 0
Study 27669971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidex OPA
Number of subjects: 0
Study 25154674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility Preservation (FP) patients
Number of subjects: 138
Study 25154674 — intervention group
Group type: COMPARATOR
Intervention: Infertile patients
Number of subjects: 138
Study 22959905 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-SC (104 mg administered at baseline and 12 weeks later)
Number of subjects: 15
Study 20625123 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (54 mg/d)
Number of subjects: 148
Study 20625123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 18581018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg of rocuronium
Number of subjects: 150
Study 18581018 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 150
Study 15851721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 1548
Study 14509173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 30
Study 14509173 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 30
Study 10595696 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg once daily (o.d.)
Number of subjects: 4000
Study 10595696 — intervention group
Group type: COMPARATOR
Intervention: Placebo o.d.
Number of subjects: 4000
Study 9092434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory mechanical left ventricular assistance
Number of subjects: 0
Study 9092434 — intervention group
Group type: COMPARATOR
Intervention: Cardiac transplantation
Number of subjects: 0
Study 2064203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 7113312 — intervention group
Group type: EXPERIMENTAL
Intervention: Profenid (3 capsules + 1 suppositorium)
Number of subjects: 38
Study 7113312 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (3 capsules + 1 suppositorium)
Number of subjects: 38
Study 2982491 — intervention group
Group type: EXPERIMENTAL
Intervention: Central IV hyperalimentation (IVH) over a 28-day period with higher caloric and protein intake for nutritionally depleted patients.
Number of subjects: 119
Study 2982491 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 119
Study 2982491 — intervention group
Group type: EXPERIMENTAL
Intervention: Central IV hyperalimentation (IVH).
Number of subjects: 119
Study 30962094 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine IXIARO®
Number of subjects: 0
Study 30962094 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine IXIARO® with TBE vaccination
Number of subjects: 0
Study 30962094 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine IXIARO® without TBE vaccination
Number of subjects: 0
Study 28533517 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vortioxetine for 14 days
Number of subjects: 96
Study 28533517 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 96
Study 27225336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 198
Study 27225336 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 198
Study 27225336 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment
Number of subjects: 198
Study 24977638 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 48